Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Abstract 5762: RPPA kinomic profiling of a tumor eradication phenotype induced by SIAH inhibition, a major tumor vulnerability in the EGFR/HER2/RAS signaling pathway, in late-stage and metastatic human cancer cell lines

Jonathan M. Baker, Andrew Howell, Daniel J. McWilliams, Ashleigh E. Hannah, Julia Wulfkuhle, Rosa Gallagher, Emanuel Petricoin, III, Amy H. Tang

Cancer Res (2025) 85 (8_Supplement_1): 5762.

https://doi.org/10.1158/1538-7445.AM2025-5762

Published: 21 April 2025

View articletitled, Abstract 5762: RPPA kinomic profiling of a tumor eradication phenotype induced by SIAH inhibition, a major tumor vulnerability in the EGFR/HER2/RAS signaling pathway, in late-stage and metastatic human cancer cell lines

Journal Articles

Abstract 2637: Investigation of cell shape, focal adhesion, and cytoskeletal changes induced by SIAH inhibition in malignant human cancer cell lines

Daniel J. McWilliams, Jonathan M. Baker, Amy H. Tang, Emanuel Petricoin, Julia Wulfkuhle, Andrew Howell

Cancer Res (2025) 85 (8_Supplement_1): 2637.

https://doi.org/10.1158/1538-7445.AM2025-2637

Published: 21 April 2025

View articletitled, Abstract 2637: Investigation of cell shape, focal adhesion, and cytoskeletal changes induced by SIAH inhibition in malignant human cancer cell lines

Journal Articles

Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models

Cancer Res (2024) 84 (17_Supplement_2): C023.

https://doi.org/10.1158/1538-7445.PANCREATIC24-C023

Published: 15 September 2024

View articletitled, Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models

Journal Articles

Abstract 1841: Investigating mechanisms of tumor eradication by blocking SIAH E3 ligase, a major tumor vulnerability, in EGFR/RAS-driven human cancer

Jonathan M. Baker, Andrew Howell, Ashleigh Hannah, Julia Wulfkuhle, Natalie Stahr, Rosa Gallagher, Emanuel Petricoin, Amy Tang

Cancer Res (2024) 84 (6_Supplement): 1841.

https://doi.org/10.1158/1538-7445.AM2024-1841

Published: 22 March 2024

View articletitled, Abstract 1841: Investigating mechanisms of tumor eradication by blocking SIAH E3 ligase, a major tumor vulnerability, in EGFR/RAS-driven human cancer

Journal Articles

Abstract A019: IGF-1R protein pathway activation is associated with pathologic complete response to an anti-IGF-1R regimen (paclitaxel, ganitumab, and metformin) in the I-SPY2 neoadjuvant breast cancer trial

Emanuel F. Petricoin, Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Laura van ‘t Veer, Rosa I. Gallagher, Gillian L. Hirst, Lamorna Brown-Swigart, Laura J. Esserman, Douglas Yee

Cancer Res (2024) 84 (3_Supplement_1): A019.

https://doi.org/10.1158/1538-7445.ADVBC23-A019

Published: 01 February 2024

View articletitled, Abstract A019: IGF-1R protein pathway activation is associated with pathologic complete response to an anti-IGF-1R regimen (paclitaxel, ganitumab, and metformin) in the I-SPY2 neoadjuvant breast cancer trial

Journal Articles

Abstract A003: Global and TNBC-specific biomarkers of sensitivity and resistance in early stage breast cancer from the I-SPY2 biomarker data compendium

Tam Binh V Bui, Denise M Wolf, Rosa I Gallagher, Julia Wulfkuhle, Christina Yau, Lamorna Brown-Swigart, Jennifer Rosenbluth, Douglas Yee, Gillian L Hirst, Laura J Esserman, Emanuel F Petricoin, Laura J Van 't Veer

Cancer Res (2024) 84 (3_Supplement_1): A003.

https://doi.org/10.1158/1538-7445.ADVBC23-A003

Published: 01 February 2024

View articletitled, Abstract A003: Global and TNBC-specific biomarkers of sensitivity and resistance in early stage breast cancer from the I-SPY2 biomarker data compendium

Journal Articles

Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements

Julia Wulfkuhle, Denise M. Wolf, Angela DeMichele, Christina Yau, Laura van ‘t Veer, Hope S. Rugo, Lajos Pusztai, Lamorna Brown-Swigart, Gillian L. Hirst, Rosa I. Gallagher, Amy L. Delson, Alexander D. Borowsky, Laura J. Esserman, Paula R. Pohlmann, Emanuel F. Petricoin

Cancer Res (2024) 84 (3_Supplement_1): A026.

https://doi.org/10.1158/1538-7445.ADVBC23-A026

Published: 01 February 2024

View articletitled, Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements

Journal Articles

Abstract LB102: Hexyl-(cuban-1-yl-methyl)-biguanide (HCB) suppresses N-glycosylation of immune checkpoint proteins B7-H3 and B7-H4, reverses tumor hypoxia, decreases intratumoral regulatory T cells, and increases intratumoral CD8+ T cells in the ovarian dependent ER+HER2- SSM2^ucd mammary cancer allograft model

Cancer Res (2023) 83 (8_Supplement): LB102.

https://doi.org/10.1158/1538-7445.AM2023-LB102

Published: 14 April 2023

View articletitled, Abstract LB102: Hexyl-(cuban-1-yl-methyl)-biguanide (HCB) suppresses N-glycosylation of immune checkpoint proteins B7-H3 and B7-H4, reverses tumor hypoxia, decreases intratumoral regulatory T cells, and increases intratumoral CD8+ T cells in the ovarian dependent ER+HER2- SSM2ucd mammary cancer allograft model

Journal Articles

Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer

Cancer Res (2023) 83 (8_Supplement): CT144.

https://doi.org/10.1158/1538-7445.AM2023-CT144

Published: 14 April 2023

View articletitled, Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer

Journal Articles

Abstract 5498: SHP2 inhibition enhances antitumor effect of mirdametinib in a pediatric brain tumor model bearing CDC42SE2BRAF fusion by rewiring the proteome and phosphoproteome landscape

Cancer Res (2023) 83 (7_Supplement): 5498.

https://doi.org/10.1158/1538-7445.AM2023-5498

Published: 04 April 2023

View articletitled, Abstract 5498: SHP2 inhibition enhances antitumor effect of mirdametinib in a pediatric brain tumor model bearing CDC42SE2BRAF fusion by rewiring the proteome and phosphoproteome landscape

Journal Articles

Abstract PD5-08: PD5-08 Drug target activation mapping of matched triple negative primary and axillary lymph node metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation

Julia Wulfkuhle, Page Blas, Heather Williams, Claudius Mueller, Rosa I. Gallagher, Mariaelena Pierobon, Joyce O’Shaughnessy, Emanuel F. Petricoin

Cancer Res (2023) 83 (5_Supplement): PD5-08.

https://doi.org/10.1158/1538-7445.SABCS22-PD5-08

Published: 01 March 2023

View articletitled, Abstract PD5-08: PD5-08 Drug target activation mapping of matched triple negative primary and axillary lymph node metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation

Journal Articles

Abstract P4-08-13: The Use of Reverse Phase Protein Arrays (RPPA), Principal Component Analysis (PCA), and CScape Pathway Mapping to Identify New Tumor Vulnerability and Actionable Targets in Human Malignant Triple-Negative Breast cancer cell lines

Andrew P. Howell, Julia Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Amy H. Tang

Cancer Res (2023) 83 (5_Supplement): P4-08-13.

https://doi.org/10.1158/1538-7445.SABCS22-P4-08-13

Published: 01 March 2023

View articletitled, Abstract P4-08-13: The Use of Reverse Phase Protein Arrays (RPPA), Principal Component Analysis (PCA), and CScape Pathway Mapping to Identify New Tumor Vulnerability and Actionable Targets in Human Malignant Triple-Negative Breast cancer cell lines

Journal Articles

Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents

Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Rosa I. Gallagher, Lamorna A. Brown Swigart, Gillian L. Hirst, Jean-Philippe Coppe, Mark Jesus M. Magbanua, Rosalyn Sayaman, I-SPY2 Investigators, Laura Sit, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Lajos Pusztai, Douglas Yee, Laura J. Esserman, Emanuel F. Petricoin, Laura Van ’t Veer

Cancer Res (2023) 83 (5_Supplement): PD5-04.

https://doi.org/10.1158/1538-7445.SABCS22-PD5-04

Published: 01 March 2023

View articletitled, Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents

Journal Articles

Abstract PD5-02: PD5-02 An Organoid Model System to Study Resistance Mechanisms, Predictive Biomarkers, and New Strategies to Overcome Therapeutic Resistance in Early-Stage Triple-Negative Breast Cancer

Tam Binh V. Bui, Denise M. Wolf, Kaitlin Moore, Isaac S. Harris, Pravin Phadatare, Christina Yau, Lamorna A. Brown Swigart, Laura J. Esserman, Jean-Philippe Coppe, Julia Wulfkuhle, Emanuel F. Petricoin, Michael Campbell, Laura M. Selfors, Deborah A. Dillon, Beth Overmoyer, Filipa Lynce, Laura Van ’t Veer, Jennifer Rosenbluth

Cancer Res (2023) 83 (5_Supplement): PD5-02.

https://doi.org/10.1158/1538-7445.SABCS22-PD5-02

Published: 01 March 2023

View articletitled, Abstract PD5-02: PD5-02 An Organoid Model System to Study Resistance Mechanisms, Predictive Biomarkers, and New Strategies to Overcome Therapeutic Resistance in Early-Stage Triple-Negative Breast Cancer

Journal Articles

Abstract 2867: Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide

Jennifer K. Richer, Nicole S. Spoelstra, Alyse Winchester, Julia Wulfkuhle, Sharon B. Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony D. Elias

Cancer Res (2021) 81 (13_Supplement): 2867.

https://doi.org/10.1158/1538-7445.AM2021-2867

Published: 01 July 2021

View articletitled, Abstract 2867: Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide

Journal Articles

Abstract PS12-06: Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC)

Cancer Res (2021) 81 (4_Supplement): PS12-06.

https://doi.org/10.1158/1538-7445.SABCS20-PS12-06

Published: 15 February 2021

View articletitled, Abstract PS12-06: Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC)

Journal Articles

Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer

Cancer Res (2021) 81 (4_Supplement): PD9-04.

https://doi.org/10.1158/1538-7445.SABCS20-PD9-04

Published: 15 February 2021

View articletitled, Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer

Journal Articles

Abstract PS12-14: Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer

Cancer Res (2021) 81 (4_Supplement): PS12-14.

https://doi.org/10.1158/1538-7445.SABCS20-PS12-14

Published: 15 February 2021

View articletitled, Abstract PS12-14: Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer

Journal Articles

Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial

Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Smita M. Asare, Gillian L. Hirst, Laura Sit, Jane Perlmutter, I-SPY 2 TRIAL Consortium, Minetta Liu, John Park, Angela DeMichele, Douglas Yee, Don Berry, Laura Esserman, Emanuel Petricoin, Laura van t' Veer

Cancer Res (2020) 80 (4_Supplement): P4-10-02.

https://doi.org/10.1158/1538-7445.SABCS19-P4-10-02

Published: 15 February 2020

View articletitled, Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial

Journal Articles

Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial

Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Emanuel Petricoin, Lamorna Brown-Swigart, Gillian Hirst, Smita Asare, I-SPY 2 Consortium, Douglas Yee, Angela DeMichele, Hope Rugo, Olufunmilayo Olopade, Rita Nanda, Minetta Liu, Laura Esserman, Laura van t' Veer

Cancer Res (2019) 79 (13_Supplement): 2679.

https://doi.org/10.1158/1538-7445.AM2019-2679

Published: 01 July 2019

View articletitled, Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 5762: RPPA kinomic profiling of a tumor eradication phenotype induced by SIAH inhibition, a major tumor vulnerability in the EGFR/HER2/RAS signaling pathway, in late-stage and metastatic human cancer cell lines

Abstract 2637: Investigation of cell shape, focal adhesion, and cytoskeletal changes induced by SIAH inhibition in malignant human cancer cell lines

Abstract C023: PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models

Abstract 1841: Investigating mechanisms of tumor eradication by blocking SIAH E3 ligase, a major tumor vulnerability, in EGFR/RAS-driven human cancer

Abstract A019: IGF-1R protein pathway activation is associated with pathologic complete response to an anti-IGF-1R regimen (paclitaxel, ganitumab, and metformin) in the I-SPY2 neoadjuvant breast cancer trial

Abstract A003: Global and TNBC-specific biomarkers of sensitivity and resistance in early stage breast cancer from the I-SPY2 biomarker data compendium

Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements

Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer

Abstract 5498: SHP2 inhibition enhances antitumor effect of mirdametinib in a pediatric brain tumor model bearing CDC42SE2BRAF fusion by rewiring the proteome and phosphoproteome landscape

Abstract PD5-08: PD5-08 Drug target activation mapping of matched triple negative primary and axillary lymph node metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation

Abstract P4-08-13: The Use of Reverse Phase Protein Arrays (RPPA), Principal Component Analysis (PCA), and CScape Pathway Mapping to Identify New Tumor Vulnerability and Actionable Targets in Human Malignant Triple-Negative Breast cancer cell lines

Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents

Abstract PD5-02: PD5-02 An Organoid Model System to Study Resistance Mechanisms, Predictive Biomarkers, and New Strategies to Overcome Therapeutic Resistance in Early-Stage Triple-Negative Breast Cancer

Abstract 2867: Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide

Abstract PS12-06: Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC)

Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer

Abstract PS12-14: Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer

Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial

Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only